Abstract:The outcome of bacterial infection management relies on prompt diagnosis and effective treatment, but conventional antimicrobial susceptibility testing can be slow and labor-intensive. Therefore, this study aims to predict phenotypic antimicrobial susceptibility of selected beta-lactam antimicrobials in the bacteria of the family Enterobacteriaceae from different beta-lactamase resistance genotypes. Using human datasets extracted from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program conducted by Pfizer and retail meat datasets from the National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS), we used a robust or weighted least square multivariable linear regression modeling framework to explore the relationship between antimicrobial susceptibility data of beta-lactam antimicrobials and different types of beta-lactamase resistance genes. In humans, in the presence of the blaCTX-M-1, blaCTX-M-2, blaCTX-M-8/25, and blaCTX-M-9 groups, MICs of cephalosporins significantly increased by values between 0.34–3.07 μg/mL, however, the MICs of carbapenem significantly decreased by values between 0.81–0.87 μg/mL. In the presence of carbapenemase genes (blaKPC, blaNDM, blaIMP, and blaVIM), the MICs of cephalosporin antimicrobials significantly increased by values between 1.06–5.77 μg/mL, while the MICs of carbapenem antimicrobials significantly increased by values between 5.39–67.38 μg/mL. In retail meat, MIC of ceftriaxone increased significantly in the presence of blaCMY-2, blaCTX-M-1, blaCTX-M-55, blaCTX-M-65, and blaSHV-2 by 55.16 μg/mL, 222.70 μg/mL, 250.81 μg/mL, 204.89 μg/mL, and 31.51 μg/mL respectively. MIC of cefoxitin increased significantly in the presence of blaCTX-M-65 and blaTEM-1 by 1.57 μg/mL and 1.04 μg/mL respectively. In the presence of blaCMY-2, MIC of cefoxitin increased by an average of 8.66 μg/mL over 17 years. Compared to E. coli isolates, MIC of cefoxitin in Salmonella enterica isolates decreased significantly by 0.67 μg/mL. On the other hand, MIC of ceftiofur increased in the presence of blaCTX-M-1, blaCTX-M-65, blaSHV-2, and blaTEM-1 by 8.82 μg/mL, 9.11 μg/mL, 8.18 μg/mL, and 1.04 μg/mL respectively. In the presence of blaCMY-2, MIC of ceftiofur increased by an average of 10.20 μg/mL over 14 years. The ability to predict antimicrobial susceptibility of beta-lactam antimicrobials directly from beta-lactamase resistance genes may help reduce the reliance on routine phenotypic testing with higher turnaround times in diagnostic, therapeutic, and surveillance of antimicrobial-resistant bacteria of the family Enterobacteriaceae.

What problem does this paper attempt to address?

The problem this paper attempts to address is estimating the phenotypic antimicrobial susceptibility of specific β-lactam antibiotics against Enterobacteriaceae through predictive models, thereby reducing the time and workload of conventional phenotypic testing. Specifically, the study aims to predict the phenotypic antimicrobial susceptibility of selected β-lactam antibiotics from different β-lactamase resistance genotypes. ### Background - **Antimicrobial Resistance (AMR)**: The increase in antimicrobial resistance has become a major global concern, especially in healthcare settings, where the irrational use of antimicrobials exacerbates the problem. - **Conventional Antimicrobial Susceptibility Testing**: Traditional phenotypic antimicrobial susceptibility testing, although reliable, is time-consuming and labor-intensive, posing a significant bottleneck in clinical management and treatment. - **Molecular Methods**: While molecular tools can accelerate the diagnosis of antimicrobial resistance, discrepancies between genotype and phenotype can lead to clinical treatment failures. ### Research Objectives - **Predictive Model**: Develop a predictive model that uses genotype and phenotype information from existing surveillance data to directly predict the phenotypic antimicrobial susceptibility of β-lactam antibiotics from β-lactamase resistance genes. - **Reduce Dependence**: Reduce reliance on conventional phenotypic testing, thereby speeding up diagnosis, improving treatment outcomes, and enhancing the clinical management of antimicrobial-resistant infections. ### Methods - **Data Sources**: - Human Dataset: From Pfizer's Antimicrobial Testing Leadership and Surveillance (ATLAS) program. - Retail Meat Dataset: From the National Antimicrobial Resistance Monitoring System (NARMS). - **Model**: Use robust or weighted least squares multivariable linear regression models to explore the relationship between antimicrobial susceptibility data of β-lactam antibiotics and different types of β-lactamase resistance genes. ### Results - **Human Dataset**: - Factors such as country, bacterial species, age group, and healthcare setting significantly affect the minimum inhibitory concentration (MIC) of β-lactam antibiotics. - The presence of specific β-lactamase genes significantly increased the MIC values of certain antibiotics, while other genes decreased the MIC values. - **Retail Meat Dataset**: - The MIC values of certain antibiotics significantly increased in the presence of different β-lactamase genes, particularly in certain bacterial genera and meat products. ### Conclusion - **Application of Predictive Models**: Predictive models can directly predict the phenotypic antimicrobial susceptibility of β-lactam antibiotics from genotype data, helping to reduce reliance on conventional phenotypic testing, speed up diagnosis, improve treatment outcomes, and enhance the clinical management of antimicrobial-resistant infections.

Predictive Modeling of Phenotypic Antimicrobial Susceptibility of Selected Beta-Lactam Antimicrobials from Beta-Lactamase Resistance Genes